Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.
Melisa Wong, MD, of the University of California, San Francisco, lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.
The study found that for every 10-year increase in age, a patient was 25% less likely to receive active care—a patient aged 70 years was 25% more likely than one aged 80 to receive active treatment for their cancer. She suggests that age bias, among other reasons, could be responsible for this gap.
FDA Approves Amivantamab Plus Chemo Combo for Advanced NSCLC With EGFR Exon 20 Insertion Mutations
March 1st 2024Amivantamab was approved by the FDA as first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations or as therapy for those whose disease progressed on or after platinum-based chemotherapy.
Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable NSCLC
March 1st 2024Treatment with neoadjuvant tislelizumab plus platinum-based doublet chemotherapy, followed by surgery and adjuvant tislelizumab, improved event-free survival in patients with resectable non–small cell lung cancer.